Observation of raltitrexed and oxalipatin combined with three-dimensional conformal radiotherapy for ad-vanced esophageal cancer
LI Defan
YANG Fan
JIANG Shunian
XU Xiujuan
LIU Bing
YAN Qingfang
Abstract：Objective To explore the efficacy and toxic reaction of three?dimensional conformal radiotherapy(3DCRT) with chemotherapy for advanced esophageal cancer. Methods From September 2011 to April 2013, 42 patients were treated by 3DCRT (DT:60 Gy) and concurrent chemotherapy using raltitrexed(3 mg/m2, d1) and oxalipatin(130 mg/m2, d2) with a 28?day cycle. The concurrent chemotherapy lasted for 2 cycles.After radiotherapy, 2 cycles of the same regimen for consolidation chemotherapy were used 4?6 weeks later. Results All patients finished the radiochemotherapy and got complete remission in 18 cases( 42?9%) , partial remis?sion in 23 cases( 54?8%) and stable disease in 1 case( 2?4%) with the rate of total efficiency of 97?6%. The 1?and 2?year local control rates and survival rates were 90?5%, 71?4% and 85?7%, 60?7%. Main side effects were grade 1?2. The incidence of acute esophagi?tis, acute radiation pneumonia, gastrointestinal reaction, bone marrow depression and liver function injury were 95?2%, 23?8%, 73?8%, 42?9% and 19?1%, respectively. Conclusion Raltitrexed and oxalipatin combined with 3DCRT for advanced esophageal cancer patients is effective and well?tolerated. The value of addition of concurrent radiochemotherapy for advanced esophageal cancer needs further investigation.
Keywords：Esophageal cancerRadiotherapyChemotherapyThree-dimensional conformal radiotherapy(3DCRT)RaltitrexedOxalipatin
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 57-60 )